Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1989 1
1990 1
1994 1
1995 1
1998 1
2002 1
2003 2
2005 1
2006 1
2009 2
2010 2
2011 1
2012 1
2013 1
2014 3
2015 5
2016 8
2017 5
2018 4
2019 2
2020 8
2021 10
2022 8
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20AJ, 5BAuthor
Page 1
Symmetry TFTs from String Theory.
Apruzzi F, Bonetti F, García Etxebarria I, Hosseini SS, Schäfer-Nameki S. Apruzzi F, et al. Commun Math Phys. 2023;402(1):895-949. doi: 10.1007/s00220-023-04737-2. Epub 2023 May 26. Commun Math Phys. 2023. PMID: 37475876 Free PMC article.
We apply this framework to 7d super-Yang Mills, where X = C2/gammaADE, as well as the Sasaki-Einstein links of Calabi-Yau three-fold cones that give rise to 5d superconformal field theories. ...
We apply this framework to 7d super-Yang Mills, where X = C2/gammaADE, as well as the Sasaki-Einstein links of Calabi-Yau three-fold …
Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001.
Gondi V, Deshmukh S, Brown PD, Wefel JS, Armstrong TS, Tome WA, Gilbert MR, Konski A, Robinson CG, Bovi JA, Benzinger TLS, Roberge D, Kundapur V, Kaufman I, Shah S, Usuki KY, Baschnagel AM, Mehta MP, Kachnic LA. Gondi V, et al. Int J Radiat Oncol Biol Phys. 2023 Nov 1;117(3):571-580. doi: 10.1016/j.ijrobp.2023.04.030. Epub 2023 May 6. Int J Radiat Oncol Biol Phys. 2023. PMID: 37150264 Clinical Trial.
Patient-reported symptom burden was assessed using the MD Anderson Symptom Inventory with Brain Tumor Module and EQ-5D-5L. RESULTS: Between July 2015 and March 2018, 518 patients were randomized. ...
Patient-reported symptom burden was assessed using the MD Anderson Symptom Inventory with Brain Tumor Module and EQ-5D-5L. RESULTS: B …
Anisotropic Strange Star in 5D Einstein-Gauss-Bonnet Gravity.
Jasim MK, Maurya SK, Singh KN, Nag R. Jasim MK, et al. Entropy (Basel). 2021 Aug 6;23(8):1015. doi: 10.3390/e23081015. Entropy (Basel). 2021. PMID: 34441155 Free PMC article.
In this paper, we investigated a new anisotropic solution for the strange star model in the context of 5D Einstein-Gauss-Bonnet (EGB) gravity. For this purpose, we used a linear equation of state (EOS), in particular pr=betarho+gamma, (where beta and gamma are const …
In this paper, we investigated a new anisotropic solution for the strange star model in the context of 5D Einstein-Gauss-Bonne …
Association between acute disease severity and one-year quality of life among post-hospitalisation COVID-19 patients: Coalition VII prospective cohort study.
Rosa RG, Cavalcanti AB, Azevedo LCP, Veiga VC, de Souza D, Dos Santos RDRM, Schardosim RFC, Rech GS, Trott G, Schneider D, Robinson CC, Haubert TA, Pallaoro VEL, Brognoli LG, de Souza AP, Costa LS, Barroso BM, Pelliccioli MP, Gonzaga J, Studier NDS, Dagnino APA, Neto JM, da Silva SS, Gimenes BDP, Dos Santos VB, Estivalete GPM, Pellegrino CM, Polanczyk CA, Kawano-Dourado L, Tomazini BM, Lisboa TC, Teixeira C, Zampieri FG, Zavascki AP, Gersh BJ, Avezum Á, Machado FR, Berwanger O, Lopes RD, Falavigna M. Rosa RG, et al. Intensive Care Med. 2023 Feb;49(2):166-177. doi: 10.1007/s00134-022-06953-1. Epub 2023 Jan 3. Intensive Care Med. 2023. PMID: 36594987 Free PMC article. Clinical Trial.
The primary outcome was the utility score of EuroQol five-dimension three-level (EQ-5D-3L). Secondary outcomes included all-cause mortality, major cardiovascular events, and new disabilities in instrumental activities of daily living. ...At 1 year, compared with severity s …
The primary outcome was the utility score of EuroQol five-dimension three-level (EQ-5D-3L). Secondary outcomes included all-cause mor …
Symptoms and Impaired Quality of Life After COVID-19 Hospitalization: Effect of Therapeutic Heparin in Non-ICU Patients in the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 Acute Trial: Effect on 3-Month Symptoms and Quality of Life.
Greenstein YY, Hubel K, Froess J, Wisniewski SR, Venugopal V, Lai YH, Berger JS, Chang SY, Colovos C, Shah F, Kornblith LZ, Lawler PR, Gaddh M, Guerrero RM, Nkemdirim W, Lopes RD, Reynolds HR, Amigo JS, Wahid L, Zahra A, Goligher EC, Zarychanski R, Leifer E, Huang DT, Neal MD, Hochman JS, Cushman M, Gong MN. Greenstein YY, et al. Chest. 2024 Apr;165(4):785-799. doi: 10.1016/j.chest.2023.11.019. Epub 2023 Nov 17. Chest. 2024. PMID: 37979717 Clinical Trial.
Individual domains assessed by the EQ-5D-5L included mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. ...Among 410 patients, 148 (36.1%) reported moderate to severe impairment in one or more domains of the EQ-5D-5L. The presence of 90- …
Individual domains assessed by the EQ-5D-5L included mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. …
Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305).
Powell LC, L'Italien G, Popoff E, Johnston K, O'Sullivan F, Harris L, Croop R, Coric V, Lipton RB. Powell LC, et al. Adv Ther. 2023 Feb;40(2):585-600. doi: 10.1007/s12325-022-02369-x. Epub 2022 Nov 22. Adv Ther. 2023. PMID: 36417057 Free PMC article. Clinical Trial.
Baseline EQ-5D utilities were similar between trial arms: 0.598 for placebo and 0.614 for rimegepant. EQ-5D improved from baseline to week 12 and utilities increased by + 0.09 for placebo and + 0.10 for rimegepant (p value = 0.011). ...
Baseline EQ-5D utilities were similar between trial arms: 0.598 for placebo and 0.614 for rimegepant. EQ-5D improved from base …
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.
Zinzani PL, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, de Oliveira JSR, Buccheri V, Perini GF, Dickinson M, McDonald A, Özcan M, Sekiguchi N, Zhu Y, Raut M, Saretsky TL, Nahar A, Kuruvilla J. Zinzani PL, et al. Blood Adv. 2022 Jan 25;6(2):590-599. doi: 10.1182/bloodadvances.2021004970. Blood Adv. 2022. PMID: 34644372 Free PMC article.
Health-related quality of life (HRQoL), measured by patient-reported outcomes (PROs) from KEYNOTE-204, are reported from patients who received 1 dose of study treatment and completed 1 PRO assessment. The EORTC QoL Questionnaire Core 30 (QLQ-C30) and EuroQoL EQ-5D were adm …
Health-related quality of life (HRQoL), measured by patient-reported outcomes (PROs) from KEYNOTE-204, are reported from patients who receiv …
Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant.
Johnston KM, L'Italien G, Popoff E, Powell L, Croop R, Thiry A, Harris L, Coric V, Lipton RB. Johnston KM, et al. Adv Ther. 2021 Oct;38(10):5209-5220. doi: 10.1007/s12325-021-01897-2. Epub 2021 Aug 29. Adv Ther. 2021. PMID: 34455556 Free PMC article. Clinical Trial.
MSQv2 was mapped to EQ-5D-3L utilities using a validated algorithm. Outcomes were assessed for the PRN arm at baseline weeks 12, 24, 36, and 52 and for the QOD + PRN arm at baseline and week 12. ...For all MSQv2 domains as well as mapped utility values, outcomes improved o …
MSQv2 was mapped to EQ-5D-3L utilities using a validated algorithm. Outcomes were assessed for the PRN arm at baseline weeks 12, 24, …
Changes in Health-related Quality of Life for Hepatitis C Virus-Infected People Who Inject Drugs While on Opioid Agonist Treatment Following Sustained Virologic Response.
Gormley MA, Akiyama MJ, Rennert L, Howard KA, Norton BL, Pericot-Valverde I, Muench S, Heo M, Litwin AH. Gormley MA, et al. Clin Infect Dis. 2022 May 3;74(9):1586-1593. doi: 10.1093/cid/ciab669. Clin Infect Dis. 2022. PMID: 34331539 Free PMC article.
EQ-5D-3L was measured at baseline; 4, 8, and 12 weeks during treatment; and 12 and 24 weeks post-treatment. Linear mixed effects regression models assessed changes in the mean EQ-5D-3L index over time. RESULTS: Mean EQ-5D-3L index baseline was 0.66 (standard …
EQ-5D-3L was measured at baseline; 4, 8, and 12 weeks during treatment; and 12 and 24 weeks post-treatment. Linear mixed effects regr …
74 results